MedWatch

FDA postpones plan for new hearing aid sales channel – again

In the US, the option to buy over-the-counter hearing aids has had multiple delays, and from the look of things now, the guidelines for the so-called OTC sales won't be nade public until early 2023 – if then.

Photo: Andrew Kelly/Reuters/Ritzau Scanpix

The farce surrounding the development of a US over-the-counter (OTC) category for the sales of low-cost hearing aids continues.

For some years, hearing aid manufacturers of all sizes and shapes have been waiting with anticipation for the US Food and Drug authority (FDA) to provide the guidelines which will define the contours of how OTC sales of hearing aids will operate in the future.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs